2024 Freshness Index... Who needs to freshen up [their pipeline]?
Of interest
1. Abbvie - almost 50% of their revenues coming from products >15 years of age, 60% > 10 years of age. If only there was a potential blockbuster AML treatment they could use to bolster their Venclexta program with, and to replace the revenue gaps created by Humira's loss of exclusivity?
2. Sanofi - 13 products in their clinical pipeline for haematology and oncology indications
3. Merck & Co (MSD) - 40% of revenues from products > 10 years old - bisantrene would pose a fantastic opportunity for the lifecycle management of Keyruda when patents expire in 2028.
4. Bristol Myers Squibb - with almost 70% of revenues coming from products > 10 years of age, and key patent expiries for Revlimid (2025/6), Eliquis (2027-29) and Opdivo (2028), BMS require additional M&A activity to bolster their pipeline.
https://www.evaluate.com/thought-leadership/the-2024-freshness-index-who-needs-to-freshen-up/#:~:text=Evaluate's%202024%20Freshness%20Index%20looks,over%2Dthe%2Dcounter%20drugs.
- Forums
- ASX - By Stock
- RAC
- Industry news
Industry news, page-1718
-
- There are more pages in this discussion • 329 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.56 |
Change
0.005(0.32%) |
Mkt cap ! $264.0M |
Open | High | Low | Value | Volume |
$1.55 | $1.56 | $1.51 | $77.12K | 50.33K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 6431 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.56 | 7 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4811 | 1.550 |
1 | 950 | 1.540 |
2 | 6560 | 1.535 |
2 | 17973 | 1.530 |
2 | 20140 | 1.525 |
Price($) | Vol. | No. |
---|---|---|
1.555 | 162 | 2 |
1.560 | 12136 | 1 |
1.565 | 3208 | 2 |
1.570 | 1594 | 1 |
1.580 | 16387 | 4 |
Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online